Safety, Resistance, and Efficacy Results from a Phase IIIb Study of Conventional- and Double-Dose Oseltamivir Regimens for Treatment of Influenza in Immunocompromised Patients

Essack Mitha(Newtown Hospital), Loreta Vareikiene(Vilnius University), Gergely Kriván(National Center for Epidemiology), Arnon Nagler(Sheba Medical Center), Sophie Le Pogam, Sally Alrabaa(University of South Florida), Analía Mykietiuk(Instituto Médico Platense), Barry Clinch(Roche (United Kingdom)), Andrew Kenwright(Roche (United Kingdom)), Frédérique Jacobs(Université Libre de Bruxelles)

Infectious Diseases and Therapy

October 30, 2019

10.1007/s40121-019-00271-8

Cited by 26

Related Papers

Nonmyeloablative Stem Cell Transplantation and Cell Therapy as an Alternative to Conventional Bone Marrow Transplantation With Lethal Cytoreduction for the Treatment of Malignant and Nonmalignant Hematologic Diseases

|Blood|1998|1.9k

Nonmyeloablative Stem Cell Transplantation and Cell Therapy as an Alternative to Conventional Bone Marrow Transplantation With Lethal Cytoreduction for the Treatment of Malignant and Nonmalignant Hematologic Diseases

|Blood|1998|1.8k

Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial

|The Lancet|2007|689

Disabling Immune Tolerance by Programmed Death-1 Blockade With Pidilizumab After Autologous Hematopoietic Stem-Cell Transplantation for Diffuse Large B-Cell Lymphoma: Results of an International Phase II Trial

|Journal of Clinical Oncology|2013|439

Deep Dermatophytosis and Inherited CARD9 Deficiency

|New England Journal of Medicine|2013|403